Graybug Vision, Inc. (NASDAQ:GRAY – Get Free Report) shares were up 12.7% during mid-day trading on Wednesday . The company traded as high as $5.34 and last traded at $5.22. Approximately 189,416 shares traded hands during mid-day trading, an increase of 8,649% from the average daily volume of 2,165 shares. The stock had previously closed at $4.63.
Graybug Vision Stock Up 12.7%
The business’s fifty day simple moving average is $3.57 and its two-hundred day simple moving average is $2.93. The company has a market cap of $8.20 million, a price-to-earnings ratio of -3.02 and a beta of 1.20.
Graybug Vision Company Profile
Graybug Vision, Inc, a clinical-stage biopharmaceutical company, focuses on the development of medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema.
Featured Articles
- Five stocks we like better than Graybug Vision
- Growth Stocks: What They Are, What They Are Not
- Post 35% Surge, Analysts Eye More Upside in Copper Giant Freeport
- What is the S&P 500 and How It is Distinct from Other Indexes
- Why a SpaceX IPO Could Be a Major Catalyst for GOOGL Stock
- Stock Dividend Cuts Happen Are You Ready?
- Can Upwork Maintain Its Comeback? Reasons to Be Bullish and Bearish
Receive News & Ratings for Graybug Vision Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Graybug Vision and related companies with MarketBeat.com's FREE daily email newsletter.
